Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Varian, Boston Scientific FDA Approvals Aid Q1 Double-Digit Stock Gains

This article was originally published in The Gray Sheet

Executive Summary

Varian Medical Systems' receipt of 510(k) clearance for its On-Board Imaging tumor tracking accessory helped the radiation oncology firm's stock soar 24.9% in the first quarter - jumping $17.21 to close at $86.31

You may also be interested in...

Lehman Brothers Global Healthcare Conference In Brief

Gen-Probe pursues HPV assay: Human papillomavirus test technology access is being sought by the company, which has held discussions with "three or four" developers thus far about potential "ways to collaborate," CFO Herm Rosenman reported March 3 at the Lehman Brothers Global Healthcare Conference in South Beach, Florida. HPV market participants include Digene (DNAwithPap) and Roche (Amplicor). Should discussions be unsuccessful, Gen-Probe "will continue to engineer our own" intellectual property to work around current barriers to entering the market, according to Rosenman. Gen-Probe projects $235 mil.-$245 mil. in revenue this year, supported by strong sales of its Tigris automated nucleic acid test platform (1"The Gray Sheet" Jan. 5, 2004, p. 5)...

Cordis Parries Taxus Approval Thrust With REALITY Procedure Success Data

Post-market surveillance of Boston Scientific's Taxus paclitaxel-eluting stent will cover over 3,500 patients and include five-year follow-up on more than 1,500 patients treated in pre-market trials

Cordis Recruits Guidant To Block Taxus, Develop Combined Delivery System

Johnson & Johnson/Cordis is betting that its drug-eluting stent marketing alliance with Guidant will allow it to match Boston Scientific's sales presence in U.S. cath labs

Related Content




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts